

510(k) SUMMARY OF SAFETY AND EFFECTIVENESS***The Trabecular Metal Technology Acetabular Augment System***

Submitter Name: Zimmer Trabecular Metal Technology

Submitter Address: 80 Commerce Drive
Allendale, New Jersey 07401-1600

Contact Person: Marci Halevi

Phone Number: (201) 818-1800 ext. 507

Fax Number: (973) 879-0825

Date Prepared: October 8, 2004

Device Trade Name: The Trabecular Metal Acetabular Augments

Device Common Name: Acetabular augmentation devices for total hip replacement acetabular components

Classification Number: 21 CFR § 888.3358

**Substantial
Equivalence:**

The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence found in the Federal Food, Drug and Cosmetic Act, as amended and as applied under 21 CFR 807, Subpart E under which a device can be marketed without premarket approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent Laws or their application by the courts.

Device Description:

The Trabecular Metal Acetabular Augments provides an alternative to structural allograft for augmenting moderate to large-sized segmental acetabular defects encountered in acetabular reconstruction. The Trabecular Metal Acetabular Augments possesses a truncated hemispherical geometry. The device is available in OD sizes 50 to 74 mm in 4 mm increments, and each size is offered in thicknesses from 5mm to 30mm in 5mm increments, aside from the 74mm implant which is available only in thicknesses of 10mm, 20mm and 30mm.

510(k) Summary (Continued)

Indications for Use: The Trabecular Metal Acetabular Augment System is intended to provide the orthopedic surgeon with a prosthetic alternative to structural allograft in cases of segmental acetabular deficiencies.

Conclusion: The Trabecular Metal Acetabular Augment System is substantially equivalent to the identified predicate devices.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

DEC 21 2004

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

Ms. Marci Halevi
Manager of Regulatory Affairs
Zimmer Trabecular Metal Technology
Zimmer, Inc.
80 Commerce Drive
Allendale, New Jersey 07401-1600

Re: K042871

Trade Name: Trabecular Metal Acetabular Augments
Regulation Number: 21 CFR 888.3358
Regulation Name: Hip joint metal/polymer/metal semi-constrained porous-coated
uncemented prosthesis
Regulatory Class: II
Product Code: LPH
Dated: October 15, 2004
Received: October 18, 2004

Dear Ms. Halevi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4659. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Celia M. Witten', with a stylized flourish at the end.

Celia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if
known):K042871

Device Name:

Trabecular Metal Acetabular Augments

Indications For Use:

Trabecular Metal Acetabular Augments are intended to provide the orthopedic surgeon with a prosthetic alternative to structural allograft in cases of segmental acetabular deficiencies.

Prescription
Use

✓

AND/OR...

Over-The-
Counter Use

(Per 21 CFR 801 Subpart D)

(21 CFR 801 Subpart C)
(Optional Format 09-2004)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH; Office of Device Evaluation (ODE)


(Division Sign-Off)

Division of General, Respiratory
and Neurological Devices

510(k) Number K042871